recall
saveHarbin Jixianglong Biotech Co., Ltd. recall (Cls II)
March 11, 2026updated 5mo ago
community read0 votes
Semaglutide, For Rx compounding use only, packaged in a) 1g, NDC 84385-106-01; b) 5g, NDC 84385-106-02; c) 10g, NDC 84385-106-06; d) 25g, NDC 84385-106-03; d) 50g, NDC 84385-106-04; e) 100g, NDC 84385-106-05Manufacturer: Harbin Jixianglong Biotech Co., Ltd., North of Baoan Road, East of Changqing Street, Limin Development Zone, Harbin, China. — Reason: CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution — Status: Ongoing
view source ↗Data sources
last refreshed 40m ago
Found something off?
same company · ±60 days · 6
- recallHarbin Jixianglong Biotech Co., Ltd. recall (Cls II)Mar 11, 2026
- approvalWEGOVY (SEMAGLUTIDE) — FDA approvalMar 19, 2026
- approvalWEGOVY (SEMAGLUTIDE) — FDA approvalMar 19, 2026
- approvalWEGOVY (SEMAGLUTIDE) — FDA approvalFeb 25, 2026
- approvalWEGOVY (SEMAGLUTIDE) — FDA approvalFeb 25, 2026
- approvalOZEMPIC (SEMAGLUTIDE) — FDA approvalJan 30, 2026
🐶 often sniffed alongside
top 7- companyNovo Nordisk Inc2 co-mentions · 2 sources
- tagHepatology2 co-mentions · 1 sources
- tagObesity2 co-mentions · 1 sources
- tagEndocrinology & Metabolism1 co-mentions · 1 sources
- drugObesity1 co-mentions · 1 sources
- drugzalfermin1 co-mentions · 1 sources
- drugcagrilintide hydrochloride1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that